Comparing the current results to its competitors, Petvivo Holdings Inc reported Revenue increase in the 1 quarter 2026 by 0 % year on year. The revenue growth was below Petvivo Holdings Inc 's competitors' average revenue growth of 3.88 %, achieved in the same quarter.
Petvivo Holdings Inc 's Comment on Competition and Industry Peers
The animal health medicines market is characterized by intense competition and substantial investment in research and development. Key participants include Zoetis, Inc.; Merck Animal Health, the animal health division of Merck & Co., Inc.; Merial, the animal health division of Sanofi S.A.; Elanco, the animal health division of Eli Lilly and Company; Bayer Animal Health, the animal health division of Bayer AG; NAH, the animal health division of Novartis AG; Boehringer Ingelheim Animal Health, the animal health division of Boehringer Ingelheim GmbH; Virbac Group; Ceva Animal Health; Vetoquinol; Dechra Pharmaceuticals PLC; and smaller early-stage companies such as Kindred Bio and Aratana Therapeutics.
Elanco Animal Health Incorporated Share Performance
+6.17%
This Year
Elanco Animal Health Incorporated
Profile
Elanco Animal Health Inc operates on a business model that focuses on the development, manufacturing, and marketing of veterinary products and services. They aim to provide innovative solutions for animal health and well-being, offering a range of products including medicines, vaccines, and feed additives. Elanco serves both companion animals and food-producing animals, catering to the diverse needs of veterinarians, farmers, and pet owners worldwide.
Verastem Inc is a biopharmaceutical company that focuses on discovering and developing medicines to treat cancer by targeting the underlying biology of the disease. They employ a research-driven business model to identify novel therapeutic candidates, evaluate their potential through preclinical and clinical trials, and bring them to market with the goal of improving patient outcomes. Verastem emphasizes innovation, precision medicine, and strategic collaborations to advance their pipeline of cancer therapeutics.
Sanofi's business model revolves around the development, production, and distribution of pharmaceutical products. They aim to innovate and provide healthcare solutions across various therapeutic areas to improve patients' lives worldwide. Sanofi collaborates with partners and healthcare professionals to ensure effective delivery of their products and to address evolving patient needs.
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
Sources:
Petvivo Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Petvivo Holdings Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
